GNMSF GENMAB A/S

NEUTRAL Impact: 2/10 6-K
Horizon immediate Filed Apr 1, 2026 Processed 2mo ago SEC 0001434265-26-000057
Notable filing: 6-K
Latest settled — T+20d ⚠ clustered
GNMSF ▼ -3.68% at T+20d
NEUTRAL call ✗ call lost -3.68% · α vs SPY -13.40% · entry $265.00 → $255.25
Next anchor: T+60d in 19d
Last close $249.45 (close Jun 8) · -5.87% from $265.00 entry
Entry anchored
Apr 1, 2026
via day open
T+1d
0.00%
call 0.00% · α -0.08%
$265.00
settled 2mo ago
T+5d
+12.60%
call +12.60% · α +8.83%
$298.38
settled 2mo ago
T+20d
-3.68%
call -3.68% · α -13.40%
$255.25
settled 6w ago
T+60d
call — · α —
in 19d

Price Chart

Loading chart...

Executive Summary

Genmab disclosed routine insider transactions involving the vesting of restricted stock units for six executive officers, including CEO Jan van de Winkel and CFO Anthony Pagano. The transactions are standard compensation events with no material financial impact.

Actionable Insight

No trading implications - this is routine insider activity related to pre-existing compensation plans. Monitor for any subsequent open market transactions which would indicate active buying or selling sentiment.

Key Facts

  • CEO Jan van de Winkel acquired 8,525 shares through RSU vesting at DKK 1,758.50 per share
  • CFO Anthony Pagano acquired 4,206 shares through RSU vesting at DKK 1,758.50 per share
  • Four other executive officers acquired between 439 and 5,186 shares through RSU vesting
  • All transactions occurred on April 1, 2026, and were net settled outside the market
  • Disclosure made pursuant to EU Market Abuse Regulation Article 19

Financial Impact

Approximately DKK 33.3 million ($4.8 million) in total share value acquired through RSU vesting

share countinsider ownership

Risk Factors

  • None - this is a standard regulatory disclosure of pre-arranged compensation events
  • Potential misinterpretation by investors as active insider buying when it is actually automatic RSU vesting

Market Snapshot

Exchange
OTC
Sector
Pharmaceutical Preparations

Documents Analyzed

This report is based on 5 SEC documents filed with EDGAR.

DocumentAccession Number
6-K Filing (Primary)0001434265-26-000057
Document: gmab_20260401xx6kx2.htm0001434265-26-000057
Document: 0001434265-26-000057-index-headers.html0001434265-26-000057
Document: 0001434265-26-000057-index.html0001434265-26-000057
Document: 0001434265-26-000057.txt0001434265-26-000057
10 reports for GNMSF
Performance horizon
Filters
Rows
Reports for GNMSF — sortable, filterable
Type Now
May 29, 2026
11d ago
6-K
NEUTRAL ★ 2/10
$251.55 $249.45▼ −0.83%▲ +1.92%$249.45 (−0.83%)
May 13, 2026
27d ago
6-K
NEUTRAL ★ 2/10
$268.24 $265.27▼ −1.11%▲ +0.05%$249.45 (−7.00%)
May 12, 2026
28d ago
6-K
NEUTRAL ★ 1/10
$264.64 $265.27▲ +0.24%▲ +0.16%$249.45 (−5.74%)
May 8, 2026
4w ago
6-K
NEUTRAL ★ 2/10
$259.60 $265.27▲ +2.18%▲ +2.27%$249.45 (−3.91%)
Apr 17, 2026
7w ago
6-K
NEUTRAL ★ 3/10
$281.75 $271.83▼ −3.52%▼ −4.08%$249.45 (−11.46%)
Apr 17, 2026
7w ago
6-K
NEUTRAL ★ 2/10
$281.75 $271.83▼ −3.52%▼ −4.08%$249.45 (−11.46%)
Apr 14, 2026
8w ago
6-K
NEUTRAL ★ 4/10
$273.25 $281.75▲ +3.11%▲ +1.72%$249.45 (−8.71%)
Apr 1, 2026
9w ago
6-K
NEUTRAL ★ 2/10
$265.00 $298.38▲ +12.60%▲ +8.83%$249.45 (−5.87%)
Apr 1, 2026
9w ago
6-K
NEUTRAL ★ 2/10
$265.00 $298.38▲ +12.60%▲ +8.83%$249.45 (−5.87%)
Mar 30, 2026
10w ago
6-K
NEUTRAL ★ 2/10
$265.00 $281.06▲ +6.06%▲ +2.12%$249.45 (−5.87%)
Showing 10 of 10

US Market Status

Market Closed — Opens in 8h 33m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access